UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also cumbersome and ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...